A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma (NCT06478693)
MTX-GPC3-303
This trial is Currently recruiting
Registration number NCT06478693
Program & service
This trial is being run with the Specialty Medicine service, and as part of the Gastroenterology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Stuart Roberts
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.